Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study

ConclusionAmong 319 patients who completed this 2-year extension of two global phase IIb studies, peficitinib 100 mg once daily demonstrated a stable safety profile and sustained effectiveness in patients with moderate-to-severe RA.Trial RegistrationClinicalTrials.gov identifier, NCT01711814. Registered 19 October 2012.FundingAstellas Pharma Global Development, Inc.

http://link.springer.com/10.1007/s40744-019-00167-6

Source: Rheumatology and Therapy - August 12, 2019 Category: Rheumatology Source Type: research